{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:44:33Z","timestamp":1788893073817,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40265-016-0551-x","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T13:34:53Z","timestamp":1456752893000},"page":"589-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antipsychotic Management of Schizoaffective Disorder: A Review"],"prefix":"10.1007","volume":"76","author":[{"given":"Jean-Pierre","family":"Lindenmayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"551_CR1","volume-title":"Dementia praecox and paraphrenia","author":"E Kraepelin","year":"1919","unstructured":"Kraepelin E. Dementia praecox and paraphrenia. Edinburgh: Livingston; 1919."},{"key":"551_CR2","doi-asserted-by":"crossref","unstructured":"Raymond Lake C. Disorders of thought are severe mood disorders: the selective attention defect in mania challenges the Kraepelinian dichotomy. A review.\u00a0Schizophr Bull. 2008;34(1):109\u201317. doi: 10.1093\/schbul\/sbm035 .","DOI":"10.1093\/schbul\/sbm035"},{"issue":"97\u2013126","key":"551_CR3","first-page":"4","volume":"13","author":"J Kasanin","year":"1933","unstructured":"Kasanin J. The acute schizoaffective psychoses. Am J Psychiatry. 1933;13(97\u2013126):4.","journal-title":"Am J Psychiatry."},{"key":"551_CR4","volume-title":"Diagnostic and statistical manual of mental disorders, third edition text revised (DSM-III-TR)","author":"American Psychiatric Association","year":"1987","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, third edition text revised (DSM-III-TR). Washington DC: APA; 1987."},{"key":"551_CR5","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.","edition":"5"},{"issue":"2","key":"551_CR6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/ps.2009.60.2.210","volume":"60","author":"M Olfson","year":"2009","unstructured":"Olfson M, Marcus SC, Wan GJ. Treatment patterns for schizoaffective disorder and schizophrenia among Medicaid patients. Psychiatr Serv. 2009;60(2):210\u20136. doi: 10.1176\/appi.ps.60.2.210 .","journal-title":"Psychiatr Serv."},{"issue":"1","key":"551_CR7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","volume":"64","author":"J Per\u00e4l\u00e4","year":"2007","unstructured":"Per\u00e4l\u00e4 J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19\u201328. doi: 10.1001\/archpsyc.64.1.19 .","journal-title":"Arch Gen Psychiatry."},{"issue":"6","key":"551_CR8","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2147\/NDT.S4120","volume":"4","author":"DJ Abrams","year":"2008","unstructured":"Abrams DJ, Rojas DC, Arciniegas DB. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatr Dis Treat. 2008;4(6):1089\u2013109. doi: 10.2147\/NDT.S4120 .","journal-title":"Neuropsychiatr Dis Treat."},{"key":"551_CR9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1192\/bjp.177.5.421","volume":"177","author":"M Harrow","year":"2000","unstructured":"Harrow M, Grossman LS, Herbener ES, Davies EW. Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry. 2000;177:421\u20136.","journal-title":"Br J Psychiatry."},{"key":"551_CR10","first-page":"1","volume":"165","author":"CJ DeFrances","year":"2007","unstructured":"DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2007;165:1\u2013209.","journal-title":"Vital Health Stat."},{"issue":"3","key":"551_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jad.2007.07.009","volume":"106","author":"E Cheniaux","year":"2008","unstructured":"Cheniaux E, Landeira-Fernandez J, Lessa Telles L, et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord. 2008;106(3):209\u201317. doi: 10.1016\/j.jad.2007.07.009 .","journal-title":"J Affect Disord."},{"issue":"12","key":"551_CR12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1176\/ps.46.12.1254","volume":"46","author":"S Kent","year":"1995","unstructured":"Kent S, Fogarty M, Yellowlees P. Heavy utilization of inpatient and outpatient services in a public mental health service. Psychiatr Serv. 1995;46(12):1254\u20137.","journal-title":"Psychiatr Serv."},{"key":"551_CR13","doi-asserted-by":"crossref","unstructured":"Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. Encephale. 2005;31(3):359\u201365 [in French].","DOI":"10.1016\/S0013-7006(05)82401-7"},{"issue":"4","key":"551_CR14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF02244982","volume":"114","author":"PE Keck Jr","year":"1994","unstructured":"Keck PE Jr, McElroy SL, Strakowski SM, West SA. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl). 1994;114(4):529\u201338. doi: 10.1007\/BF02244982 .","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"551_CR15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.euroneuro.2011.03.001","volume":"21","author":"A Murru","year":"2011","unstructured":"Murru A, Pacchiarotti I, Nivoli AM, Grande I, Colom F, Vieta E. What we know and what we don\u2019t know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol. 2011;21(9):680\u201390. doi: 10.1016\/j.euroneuro.2011.03.001 .","journal-title":"Eur Neuropsychopharmacol."},{"issue":"8","key":"551_CR16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1176\/ajp.156.8.1138","volume":"156","author":"DF Levinson","year":"1999","unstructured":"Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder andschizophrenia with mood symptoms. Am J Psychiatry. 1999;156(8):1138\u201348.","journal-title":"Am J Psychiatry."},{"issue":"3","key":"551_CR17","first-page":"15","volume":"6","author":"E Cascade","year":"2009","unstructured":"Cascade E, Kalali AH, Buckley P. Treatment of schizoaffective disorder. Psychiatry (Edgmont). 2009;6(3):15\u20137.","journal-title":"Psychiatry (Edgmont)."},{"issue":"1","key":"551_CR18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2009.01424.x","volume":"121","author":"M J\u00e4ger","year":"2010","unstructured":"J\u00e4ger M, Becker T, Weinmann S, Frasch K. Treatment of schizoaffective disorder: a challenge for evidence-based psychiatry. Acta Psychiatr Scand. 2010;121(1):22\u201332. doi: 10.1111\/j.1600-0447.2009.01424.x .","journal-title":"Acta Psychiatr Scand."},{"key":"551_CR19","doi-asserted-by":"crossref","unstructured":"First MB. Towards harmonization: an annotated guide to differences in the DSM-IV and ICD-10 definitions of mental disorders. 2007: p. 24 [online]. Available from: http:\/\/bjp.rcpsych.org\/content\/bjprcpsych\/suppl\/2009\/11\/02\/195.5.382.DC1\/bjp_195_ds382.pdf . Accessed 18 Sept 2015.","DOI":"10.1192\/bjp.bp.108.060822"},{"issue":"6","key":"551_CR20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/YIC.0b013e32816f7779","volume":"22","author":"D Zimbroff","year":"2007","unstructured":"Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol. 2007;22(6):363\u201370.","journal-title":"Int Clin Psychopharmacol."},{"issue":"4","key":"551_CR21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e31817e63a5","volume":"28","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392\u2013400. doi: 10.1097\/JCP.0b013e31817e63a5 .","journal-title":"J Clin Psychopharmacol."},{"key":"551_CR22","first-page":"91","volume":"5","author":"L Iz\u00e1kov\u00e1","year":"2009","unstructured":"Iz\u00e1kov\u00e1 L, Andre I, Halaris A. Combination therapy or monotherapy for the depressed type of schizoaffective disorder. Neuropsychiatr Dis Treat. 2009;5:91\u2013101.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"1\u20132","key":"551_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jad.2008.12.017","volume":"115","author":"ID Glick","year":"2009","unstructured":"Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assun\u00e7\u00e3o-Talbott S. Theefficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009;115(1\u20132):18\u201326. doi: 10.1016\/j.jad.2008.12.017 .","journal-title":"J Affect Disord."},{"issue":"5","key":"551_CR24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.09m05564yel","volume":"71","author":"CM Canuso","year":"2010","unstructured":"Canuso CM, Lindenmayer JP, Kosik-Gonzalez C, Turkoz I, Carothers J, Bossie CA, Schooler NR. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. J Clin Psychiatry. 2010;71(5):587\u201398. doi: 10.4088\/JCP.09m05564yel .","journal-title":"J Clin Psychiatry."},{"issue":"5","key":"551_CR25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0b013e3181eeb600","volume":"30","author":"CM Canuso","year":"2010","unstructured":"Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and\/or mood stabilizers. J Clin Psychopharmacol. 2010;30(5):487\u201395. doi: 10.1097\/JCP.0b013e3181eeb600 .","journal-title":"J Clin Psychopharmacol."},{"issue":"5 Suppl","key":"551_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/0269881105056515","volume":"19","author":"A Mohl","year":"2005","unstructured":"Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Br\u00e4unig P, Medori R. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol. 2005;19(5 Suppl):22\u201331.","journal-title":"J Psychopharmacol."},{"issue":"2","key":"551_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","volume":"26","author":"BJ Kinon","year":"2006","unstructured":"Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006;26(2):157\u201362.","journal-title":"J Clin Psychopharmacol."},{"key":"551_CR28","doi-asserted-by":"crossref","unstructured":"Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006;26(5):453\u201361 (Erratum in: J Clin Psychopharmacol. 2009 Apr;29(2):169).","DOI":"10.1097\/01.jcp.0000236658.16286.25"},{"issue":"5","key":"551_CR29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/YIC.0b013e32832c2624","volume":"24","author":"K Alptekin","year":"2009","unstructured":"Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229\u201338. doi: 10.1097\/YIC.0b013e32832c2624 .","journal-title":"Int Clin Psychopharmacol."},{"issue":"10","key":"551_CR30","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.4088\/JCP.09m05154yel","volume":"70","author":"JM Kane","year":"2009","unstructured":"Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assun\u00e7\u00e3o-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348\u201357. doi: 10.4088\/JCP.09m05154yel .","journal-title":"J Clin Psychiatry."},{"key":"551_CR31","doi-asserted-by":"crossref","unstructured":"Smeraldi E, Cavallaro R, Folnegovi\u0107-\u0160malc V, Bidzan L, Emin Ceylan M, Schreiner A. Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Ther Adv Psychopharmacol. 2013;3(4):191\u20139. doi: 10.1177\/2045125313479127 .","DOI":"10.1177\/2045125313479127"},{"issue":"3","key":"551_CR32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/YIC.0000000000000017","volume":"29","author":"M Fiorino Di","year":"2014","unstructured":"Di Fiorino M, Montagnani G, Trespi G, Kasper S. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. Int Clin Psychopharmacol. 2014;29(3):166\u201376. doi: 10.1097\/YIC.0000000000000017 .","journal-title":"Int Clin Psychopharmacol."},{"issue":"3","key":"551_CR33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","volume":"76","author":"DJ Fu","year":"2015","unstructured":"Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015;76(3):253\u201362. doi: 10.4088\/JCP.14m09416 .","journal-title":"J Clin Psychiatry."},{"issue":"9","key":"551_CR34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63(9):763\u201371.","journal-title":"J Clin Psychiatry."},{"issue":"7","key":"551_CR35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681\u201390.","journal-title":"Arch Gen Psychiatry."},{"issue":"3","key":"551_CR36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","volume":"36","author":"AS Kemp","year":"2010","unstructured":"Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dub\u00e9 S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010;36(3):504\u20139. doi: 10.1093\/schbul\/sbn110 (Epub 2008 Aug 22).","journal-title":"Schizophr Bull."},{"issue":"5","key":"551_CR37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2012.01837.x","volume":"125","author":"A Murru","year":"2012","unstructured":"Murru A, Pacchiarotti I, Nivoli AM, Bonnin CM, Patrizi B, Amann B, Vieta E, Colom F. Rates and clinical correlates of treatment non-adherence in schizoaffective bipolar patients. Acta Psychiatr Scand. 2012;125(5):412\u20138. doi: 10.1111\/j.1600-0447.2012.01837.x .","journal-title":"Acta Psychiatr Scand."},{"issue":"3","key":"551_CR38","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jad.2013.08.026","volume":"151","author":"A Murru","year":"2013","unstructured":"Murru A, Pacchiarotti I, Amann BL, Nivoli AM, Vieta E, Colom F. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord. 2013;151(3):1003\u20138. doi: 10.1016\/j.jad.2013.08.026 .","journal-title":"J Affect Disord."},{"issue":"7","key":"551_CR39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4088\/JCP.08m04221","volume":"70","author":"JP Lindenmayer","year":"2009","unstructured":"Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, Chen L, Adams DH, Ascher-Svanum H, Buckley PF, Citrome L, Volavka J. Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry. 2009;70(7):990\u20136. doi: 10.4088\/JCP.08m04221 .","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"551_CR40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","volume":"35","author":"G Pandina","year":"2011","unstructured":"Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, Simpson G. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218\u201326. doi: 10.1016\/j.pnpbp.2010.11.008 .","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"6","key":"551_CR41","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125\u201332.","journal-title":"Am J Psychiatry."},{"issue":"4","key":"551_CR42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","volume":"115","author":"HA Nasrallah","year":"2007","unstructured":"Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260\u20137.","journal-title":"Acta Psychiatr Scand."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0551-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0551-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T02:14:08Z","timestamp":1692238448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0551-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0551-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]}}}